Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 07, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10thMarlborough, Massachusetts--(News ...

Here are two stocks with buy rank and strong value characteristics for investors to consider today, April 23:Phio Pharmaceuticals Corp. (PHIO) : This immuno-oncology biotech company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 14.4% over the last 60 days.Phio Pharmaceuticals has a price-to-earnings ratio (P/E) of 0.66 compared with 7.20 for the industry. The company possesses a Value Scoreof B.Transportadora de Gas del Sur S.A. (TGS) : T ...

Core Viewpoint - Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to advance its Phase 1b clinical trial of PH-762, a siRNA compound targeting skin cancer, to the fourth dose escalation cohort, indicating a supportive safety profile in the previous cohort [1][2]. Group 1: Clinical Trial Details - The Phase 1b clinical trial is a multi-center, dose-escalating study aimed at evaluating the safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma [2][6]. - In the third cohort, three patients with cutaneous squamous cell carcinoma were enrolled, and the injections were well tolerated with no serious adverse events or dose-limiting toxicities reported [2][4]. - Previous cohorts included seven patients, with the second cohort showing two patients achieving a complete response (100% tumor clearance) and one patient showing a partial response (90% clearance) [4]. Group 2: Company Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][6]. - The lead product candidate, PH-762, is designed to silence the PD-1 gene, which is implicated in various forms of skin cancer, and is being evaluated as a potential non-surgical treatment option [6][5]. - The company expresses optimism that PH-762 may provide a viable alternative to existing therapies for skin cancer [5].

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894April 03, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36304 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

Exhibit 99.1 Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3 Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-March 31, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more ef ...

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update March 31, 2025 4:00 PM EDT | Source: Phio Pharmaceuticals Corp. Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3rd Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing te ...

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual MeetingInterim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarch 10, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene si ...

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation StudyMarch 05, 2025 7:45 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio annou ...

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of DirectorsFebruary 20, 2025 7:45 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of ...